查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004184

BETA-內醯胺類和BETA-內醯胺酶抑制劑市場：依藥物類別、給藥途徑、病患群體、應用和最終用戶分類－2026-2032年全球市場預測

Beta Lactam & Beta Lactamase Inhibitors Market by Drug Class, Route of Administration, Patient Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，BETA-內醯胺類和BETA-內醯胺酶抑制劑市值將達到 309.8 億美元，到 2026 年將成長至 323.5 億美元，到 2032 年將達到 425.8 億美元，複合年成長率為 4.64%。

主要市場統計數據
基準年 2025 309.8億美元
預計年份：2026年 323.5億美元
預測年份 2032 425.8億美元
複合年成長率 (%) 4.64%

權威概述了BETA-內醯胺類和BETA-內醯胺酶抑制劑的臨床重要性、科學複雜性和策略背景。

BETA-內醯胺類抗生素及其輔助藥物—BETA-內醯胺酶抑制劑，仍然是現代抗菌治療的基石，支撐著從急診醫學到複雜住院患者管理等常規臨床實踐。已確立的藥物類別－碳青黴烯類、頭孢菌素類、單環胺基類和青黴素類－及其與不斷演變的抗藥性機制的相互作用，持續影響著治療決策、監管重點以及研發投入。過去十年，臨床醫生和政策制定者透過重新聚焦聯合治療、合理用藥方案以及標靶開發能夠恢復傳統BETA-內醯胺類抗生素活性的抑制劑，來應對日益嚴重的抗菌藥物抗藥性問題。

對重塑BETA-內醯胺類藥物研發和臨床應用的科學、監管、診斷和供應鏈因素進行綜合分析。

在科學、監管和技術因素的驅動下，BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑的治療模式正在經歷一系列變化。在科學方面，化學家和生物學家正在改進抑制劑骨架，以擴大其對更多種類BETA-內醯胺酶的活性。同時，轉化研究優先開發能夠維持對多重抗藥性革蘭氏陰性菌療效的聯合治療。這些進展與診斷準確性的提高並進。快速分子檢測和以抗菌藥物管理為重點的照護現場（POC​​）工具能夠實現治療的早期升級和靶向升級，從而改變處方模式並影響藥物研發的優先順序。

對關稅趨勢和貿易政策考量如何影響抗生素產品組合供應鏈的韌性、籌資策略和商業規劃進行基於證據的評估。

影響貿易和關稅的政策變化可能對複雜的藥品供應鏈造成毀滅性打擊，而圍繞2025年美國關稅的爭論正促使相關人員重新評估其採購、生產和合約安排。由於活性藥物成分（API）和關鍵中間體通常在地理位置集中的叢集生產，關稅導致的進口成本增加和複雜的海關程序可能會波及採購預算、契約製造計劃和庫存策略。為此，製造商和買家正尋求透過增加API供應商的地理多元化、加強安全庫存以及將關鍵生產過程到近岸地區來保護基本抗生素的供應免受政策變化的影響。

將藥物類別、給藥途徑、患者人口統計特徵、臨床應用和最終用戶趨勢聯繫起來的詳細細分分析，有助於制定開發和商業化策略。

透過按藥物類別、給藥途徑、患者類型、適應症和最終用戶分析BETA-內醯胺類和BETA-內醯胺酶抑制劑領域的細分市場趨勢，可以發現不同的機會和業務挑戰。藥物類別細分包括碳青黴烯類、頭孢菌素類、單環胺基類和青黴素類。在碳青黴烯類藥物中，多利培南、厄他培南、ImipenemMeropenem等不同分子表現出不同的抗菌頻譜和藥物動力學特徵，從而影響醫院的處方集決策和經驗性治療通訊協定。頭孢菌素類涵蓋第一代至第五代藥物，每種藥物對革蘭氏陰性菌和革蘭氏陽性菌的抗菌頻譜均不同。這些世代差異顯著影響抗藥性模式及其在指引建議中的位置。青黴素，包括氨基青黴素、頻譜青黴素和天然青黴素，在社區醫療保健和醫院環境中繼續發揮重要作用，與標靶抑制劑聯合使用時，通常作為核心藥物發揮作用。

詳細的區域分析表明，臨床實踐、監管政策、生產能力和採購模式正在塑造世界主要地區的戰略重點。

臨床實務、法規結構、生產能力和公共衛生優先事項的區域差異，影響關鍵地區BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑療法的應用、研發和供應。在美洲，監管機構和臨床網路高度重視合理使用抗生素、以醫院為中心的治療路徑，以及體現縮短住院時間和預防併發症等價值觀的適應症選擇。美國仍然是後期臨床研發和先進診斷技術的中心，支付方越來越關注基於療效的合約和真實世界數據，以此作為報銷決策的依據。

影響公司如何開發、生產和銷售BETA-內醯胺類療法和互補抑制劑的策略性企業行為和夥伴關係模式。

抗生素和抑制劑領域的企業策略正朝著幾個長期發展方向靠攏：風險共擔的合作模式、聚焦研發管線、產品組合最佳化以及業務永續營運。創新製藥公司擴大與專業生物技術公司和合約研究機構合作，以確保獲得新型化學結構，並分擔早期研發的成本和風險。同時，學名藥和專利到期藥生產商正努力透過最佳化生產效率和研發差異化製劑（例如高濃度靜脈製劑和便於患者使用的口服減重療法）來維持其臨床療效。

為產業、臨床實務和政策制定者提供實際有效的建議，以加強抗生素的價值鏈，加速抗生素的普及應用，並保護其治療價值。

產業、臨床和政策制定者應採取務實且多管齊下的方法，在確保藥物可及性的同時，兼顧治療價值和商業性價值。首先，各機構應優先考慮價值鏈多元化。這包括認證多家活性原料藥(API) 和製劑供應商，探索區域性生產方案，並實施穩健的庫存管理和緊急時應對計畫，以減輕政策和貿易相關干擾的影響。其次，調整研發組合，確保滿足尚未滿足的重大需求，並優先研發與快速分子診斷相容的聯合治療，可以加速藥物推廣應用，提高支付方的接受度。第三，企業應儘早投資建構符合醫院和支付方決策標準的真實世界數據 (REW) 和藥物經濟學模型，以支持報銷談判和處方集。

一個透明、嚴謹的多面向研究框架，整合了臨床證據、專家訪談、監管分析和供應鏈情境檢驗，以支持策略決策。

本分析所依據的研究採用多方法整合策略，旨在融合科學、臨床、監管和營運觀點。主要研究包括對感染疾病醫生、醫院藥劑師、法規事務專業人員、生產專家和供應鏈經理進行結構化訪談，以了解第一線決策和營運限制。次要研究整合了同儕審查的臨床文獻、監管指導文件、臨床試驗註冊資料和產品說明，以建構按適應症分類的療效、安全性和使用模式的全面證據基礎。此外，還分析了公共文件和產業報告，以評估關稅和貿易政策趨勢對採購和生產策略的潛在影響。

對策略挑戰和未來優先事項進行簡明扼要的整合，總結瞭如何將臨床發現與營運系統和永續的治療結果聯繫起來。

抗生素抗藥性、診斷技術創新、不斷變化的監管環境以及供應鏈重組等多重壓力，共同構成了一個複雜但可控的BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑的研發和應用環境。治療的成功不僅取決於科學創新，還取決於展現實際的臨床價值、維持可靠的供應鏈以及與合理的用藥和診斷流程無縫銜接。那些將研發重點與診斷能力結合、投資於供應鏈韌性並積極與支付方和醫療系統合作的機構，將更有利於實現臨床獲益和永續的商業性成果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：BETA-內醯胺類和BETA-內醯胺酶抑制劑市場：依藥物類別分類

  • 碳青黴烯類
    • 多利培南
    • 艾爾他培南
    • Imipenem
    • Meropenem
  • 頭孢菌素
    • 第五代頭孢菌素
    • 第一代頭孢菌素
    • 第四代頭孢菌素
    • 第二代頭孢菌素
    • 第三代頭孢菌素
  • 單環胺基類
  • 青黴素
    • 氨基青黴素
    • 頻譜青黴素
    • 天然青黴素

第9章 BETA-內醯胺類和BETA-內醯胺酶抑制劑市場：依給藥途徑分類

  • 口服
    • 膠囊
    • 藥片
  • 腸外給藥
    • 肌肉內部
    • 靜脈注射

第10章：依病患類型分類的BETA-內醯胺類和BETA-內醯胺酶抑制劑市場

  • 成年患者
    • 中年人
    • 老年人
    • 青年人
  • 兒童患者
    • 青年
    • 兒童
    • 嬰兒
    • 新生

第11章 BETA-內醯胺類和BETA-內醯胺酶抑制劑市場：依應用領域分類

  • 婦科感染疾病
  • 腹腔內感染疾病
  • 術中預防
  • 呼吸道感染疾病
  • 皮膚感染疾病
    • 蜂窩組織炎
    • 丹毒
    • 膿皰瘡
  • 尿道感染
    • 急性尿道感染
    • 慢性尿道感染

第12章 BETA-內醯胺類和BETA-內醯胺酶抑制劑市場：依最終用戶分類

  • 學術機構
  • 診所
  • 醫院
  • 研究機構

第13章 BETA-內醯胺類和BETA-內醯胺酶抑制劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 BETA-內醯胺類和BETA-內醯胺酶抑制劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 BETA-內醯胺類和BETA-內醯胺酶抑制劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國BETA-內醯胺類與BETA-內醯胺酶抑制劑市場

第17章：中國BETA-內醯胺類和BETA-內醯胺酶抑制劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Aurobindo Pharma Limited
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Centrient Pharmaceuticals Netherlands BV
  • Cipla Ltd.
  • Creative Diagnostics
  • F. Hoffmann-La Roche AG
  • Marubeni Corporation
  • Melinta Therapeutics, LLC
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Protech Telelinks
  • Qpex Biopharma, Inc. by Shionogi Inc.
  • SciClone Pharmaceuticals（Holdings）Limited
  • Sumitomo Pharma Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • TOKU-E
  • Venatorx Pharmaceuticals, Inc.
  • Zai Lab Limited
Product Code: MRR-450A0628C441

The Beta Lactam & Beta Lactamase Inhibitors Market was valued at USD 30.98 billion in 2025 and is projected to grow to USD 32.35 billion in 2026, with a CAGR of 4.64%, reaching USD 42.58 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 30.98 billion
Estimated Year [2026] USD 32.35 billion
Forecast Year [2032] USD 42.58 billion
CAGR (%) 4.64%

An authoritative overview framing the clinical importance, scientific complexity, and strategic context of beta-lactam and beta-lactamase inhibitor therapeutics

Beta-lactam antibiotics and their companion beta-lactamase inhibitors remain foundational pillars of modern antimicrobial therapy, underpinning routine clinical practice from emergency care to complex inpatient management. The interplay between established drug classes such as carbapenems, cephalosporins, monobactams, and penicillins and evolving resistance mechanisms continues to shape therapeutic decision-making, regulatory priorities, and R&D investment. Over the past decade, clinicians and policy makers have responded to rising antimicrobial resistance with renewed emphasis on combination therapies, stewardship programs, and targeted development of inhibitors that restore the activity of legacy beta-lactams.

Concurrently, advances in molecular diagnostics, pharmacokinetics, and formulation science have refined how these agents are deployed across diverse patient populations and clinical settings. These technical and operational shifts are not discrete; they coalesce into a complex environment where scientific innovation must align with supply chain resilience, reimbursement structures, and public health imperatives. Against this backdrop, stakeholders require clear, actionable intelligence that synthesizes clinical evidence, regulatory signals, and system-level dynamics to inform product strategies, clinical development plans, and market access pathways. This report provides that structured perspective and equips decision-makers with the context necessary to navigate both persistent challenges and emerging opportunities.

A synthesized analysis of the scientific, regulatory, diagnostic, and supply chain forces reshaping the development and clinical deployment of beta-lactam-based therapies

The therapeutic landscape for beta-lactams and beta-lactamase inhibitors is undergoing a sequence of transformative shifts driven by scientific, regulatory, and technological forces. On the scientific front, chemists and biologists have refined inhibitor scaffolds to broaden activity against diverse beta-lactamases, while translational research has prioritized combinations that preserve efficacy against multidrug-resistant Gram-negative organisms. These advances are running in parallel with improvements in diagnostic precision: rapid molecular assays and stewardship-focused point-of-care tools are enabling earlier de-escalation or targeted escalation of therapy, thereby changing prescribing patterns and influencing drug development priorities.

Regulatory and payer environments are also evolving, with accelerated approval pathways and value-based contracting models encouraging innovation that demonstrably improves clinical outcomes or reduces hospital resource utilization. Manufacturing and supply chain strategies have shifted from cost-centric to resilience-centric models, catalyzed by global disruptions that highlighted the risks of concentrated production footprints. Finally, cross-sector collaboration among academia, biotech innovators, and larger pharmaceutical firms has become more common, enabling shared risk for difficult-to-develop molecules while leveraging complementary capabilities. Together, these shifts are enabling a more nuanced approach to antibiotic stewardship, clinical deployment, and commercial strategy that balances efficacy, access, and sustainability.

An evidence-based appraisal of how tariff dynamics and trade policy considerations are influencing supply chain resilience, sourcing strategies, and commercial planning for antibiotic portfolios

Policy shifts affecting trade and tariffs can exert outsized effects on complex pharmaceutical supply chains, and the discourse around United States tariffs in 2025 has prompted stakeholders to re-evaluate sourcing, manufacturing, and contractual arrangements. Pharmaceutical active pharmaceutical ingredients and key intermediates are often produced in geographically concentrated clusters; any tariff-driven increase in import costs or customs complexity can ripple through procurement budgets, contract manufacturing timelines, and inventory strategies. In response, manufacturers and purchasers have been exploring greater geographic diversification of API suppliers, increased safety stock, and nearshoring of critical production steps to insulate essential antibiotic supply from policy volatility.

Beyond direct cost implications, tariff dynamics influence strategic investment decisions. Developers weighing late-stage trials or scaling production may adjust timelines or negotiate alternate supply agreements to preserve margins and delivery reliability. Health systems and payers may respond by tightening sourcing criteria or prioritizing suppliers with demonstrable supply continuity. At the same time, tariffs can accelerate domestic capacity-building initiatives as governments and industry seek to reduce strategic dependence on single-source geographies; those initiatives include incentives for manufacturing upgrades, streamlined regulatory support for facility qualification, and public-private partnerships. Taken together, the cumulative impact of tariff policy considerations in 2025 and beyond has been to sharpen focus on supply chain resilience, to encourage investment in diversified manufacturing footprints, and to elevate contractual and operational risk management as core components of commercial planning.

In-depth segmentation intelligence linking drug class, administration route, patient demographics, clinical applications, and end-user dynamics to inform development and commercialization strategy

Segment-level dynamics within the beta-lactam and beta-lactamase inhibitor space reveal differentiated opportunities and operational imperatives when analyzed across drug class, route of administration, patient type, application, and end user. Drug class segmentation encompasses carbapenems, cephalosporins, monobactam, and penicillins. Within carbapenems, distinct molecules such as doripenem, ertapenem, imipenem, and meropenem exhibit varied spectrum and pharmacokinetic profiles that influence hospital formulary decisions and empirical therapy protocols. Cephalosporins span first- through fifth-generation agents with differing Gram-negative and Gram-positive coverage, and these generational differences meaningfully affect positioning relative to resistance patterns and guideline recommendations. Penicillins, including aminopenicillins, extended-spectrum penicillins, and natural penicillins, retain key roles across community and hospital settings and often serve as backbone agents when coupled with targeted inhibitors.

Route-of-administration segmentation separates oral administration and parenteral administration. Oral options, delivered as capsules or tablets, support outpatient stewardship strategies, step-down therapy, and continuity of care post-discharge, while parenteral administration via intramuscular or intravenous routes remains essential for severe infections and inpatient management. Patient-type segmentation distinguishes adult and pediatric populations, with adults further stratified into young, middle-aged, and senior cohorts and pediatric classification including adolescents, children, infants, and neonates; each demographic subgroup presents unique pharmacokinetic considerations, dosing strategies, and safety profiles that affect clinical development and labeling decisions. Application-based segmentation covers gynecological, intra-abdominal, intraoperative prophylaxis, respiratory, skin, and urinary tract infections; skin indications further break down into cellulitis, erysipelas, and impetigo, and urinary tract infections distinguish acute from chronic presentations. These clinical use-cases drive differentiation in formulation, duration of therapy, and evidence generation needs. Finally, end-user segmentation includes academic institutions, clinics, hospitals, and research laboratories, each with distinct procurement cycles, clinical governance frameworks, and evidence thresholds for adopting new combinations or formulations. Understanding these layered segments enables developers and commercial teams to align clinical trials, regulatory strategies, and go-to-market plans with the nuanced requirements of prescribers, payers, and institutional buyers.

A nuanced regional synthesis showing how clinical practice, regulatory policy, manufacturing capacity, and procurement models shape strategic priorities across major global geographies

Regional variation in clinical practice, regulatory frameworks, manufacturing capacity, and public health priorities shapes the adoption, development, and supply of beta-lactam and beta-lactamase inhibitor therapies across major geographies. In the Americas, regulatory authorities and clinical networks place strong emphasis on antimicrobial stewardship, hospital-centric treatment pathways, and coverage decisions that reflect value in reducing length of stay and preventing complications. The United States remains a hub for late-stage clinical development and advanced diagnostics, with payers increasingly focused on outcomes-based contracting and real-world evidence to inform reimbursement.

Europe, Middle East & Africa present a heterogeneous landscape where national-level procurement practices, variable access to diagnostics, and differing reimbursement models lead to distinct regional strategies. Several European countries emphasize centralized procurement and tight stewardship protocols, while some Middle East and African markets prioritize access and capacity-building, creating avenues for tailored access programs and tiered pricing arrangements. Asia-Pacific combines dynamic demand with concentrated manufacturing capabilities and regulatory modernization. Several markets in Asia-Pacific have become major production centers for APIs and finished formulations, while others are substantial demand centers owing to high infectious disease burden and growing healthcare infrastructure investment. Regional regulatory harmonization efforts, clinical trial site availability, and local manufacturing incentives all play roles in shaping how companies prioritize launches, scale production, and structure distribution networks. Cross-regional strategies that account for these differences in clinical practice, policy environment, and industrial capability will be essential for effective global deployment of new therapeutic combinations and stewardship-aligned access models.

Strategic corporate behaviors and partnership models that are shaping how organizations develop, manufacture, and commercialize beta-lactam therapies and complementary inhibitors

Company strategies in the antibiotic and inhibitor domain are coalescing around several enduring themes: risk-sharing collaborations, focused pipelines, portfolio optimization, and operational resilience. Innovator organizations are increasingly partnering with specialized biotech firms or contract research organizations to access novel chemotypes and to share the costs and risks of early development. Simultaneously, generics and off-patent manufacturers are optimizing production efficiency and pursuing differentiated formulations, such as high-concentration intravenous presentations or patient-friendly oral step-down options, to maintain clinical relevance.

Across the competitive landscape, firms are prioritizing assets that address high unmet clinical need or that restore activity to existing beta-lactams in the face of specific resistance mechanisms. Licensing agreements and co-development partnerships enable speed-to-market while spreading technical risk, and companies are investing in manufacturing flexibility to adapt to regional demand and policy shifts. Contract manufacturing organizations and research laboratories play pivotal roles in scaling production and supporting complex analytical validation. Moreover, firms are increasingly integrating real-world evidence generation and health-economic modeling into development plans to support reimbursement negotiations and to demonstrate comparative value to payers and hospital procurement committees. Taken together, these strategic behaviors underscore a sector moving toward more collaborative, evidence-driven, and operationally resilient models of product development and commercialization.

Practical and high-impact recommendations for industry, clinical, and policy leaders to strengthen supply chains, accelerate adoption, and safeguard therapeutic value in antibiotics

Leaders across industry, clinical practice, and policy should adopt a pragmatic, multi-dimensional approach to capture therapeutic and commercial value while safeguarding access. First, organizations should prioritize supply chain diversification by qualifying multiple API and finished-dosage form suppliers, exploring regional manufacturing options, and implementing robust inventory and contingency planning to mitigate policy or trade-related disruptions. Second, aligning R&D portfolios to prioritize combinations that demonstrably address high clinical unmet need and that are compatible with rapid molecular diagnostics will enhance adoption and payer receptivity. Third, companies should invest in early generation of real-world evidence and pharmacoeconomic models tailored to hospital and payer decision criteria to support reimbursement discussions and formulary inclusion.

Fourth, forging partnerships with diagnostic developers, health systems, and stewardship coalitions will improve appropriate use and strengthen clinical value propositions. Fifth, engage proactively with regulatory agencies to explore streamlined pathways and adaptive trial designs that can accelerate access for high-need indications while maintaining rigorous safety and efficacy standards. Sixth, develop tailored regional access plans that account for local formularies, procurement mechanisms, and capacity constraints, leveraging tiered pricing or managed entry agreements where appropriate. Finally, embed antimicrobial stewardship principles into commercial strategies to ensure long-term efficacy and societal value of new therapeutic combinations. These coordinated actions will help organizations balance near-term commercial imperatives with the broader public health mandate to preserve antibiotic effectiveness.

A transparent and rigorous multi-method research framework integrating clinical evidence, expert interviews, regulatory analysis, and supply chain scenario testing to inform strategic decisions

The research underpinning this analysis draws on a multi-method approach designed to integrate scientific, clinical, regulatory, and operational perspectives. Primary research included structured interviews with infectious disease clinicians, hospital pharmacists, regulatory affairs experts, manufacturing specialists, and supply chain managers to capture frontline decision-making and operational constraints. Secondary research synthesized peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and product monographs to build a comprehensive evidence base on efficacy, safety, and indication-specific use patterns. In addition, public policy documents and trade reports were analyzed to assess potential impacts of tariff and trade policy developments on procurement and manufacturing strategies.

Supply chain mapping exercises and scenario-based stress tests were employed to identify vulnerabilities and mitigation levers across sourcing, production, and distribution. Health technology assessment frameworks and pharmacoeconomic modeling informed the evaluation of payer-relevant value drivers without producing quantitative market estimations. Where appropriate, cross-validation with expert panels ensured that conclusions reflect clinical reality and operational feasibility. This convergent methodology supports robust qualitative insights while preserving transparency about data sources and analytical assumptions.

A concise synthesis of strategic imperatives and forward-looking priorities that summarize how to translate clinical insight into operational readiness and sustainable therapeutic impact

The convergence of antimicrobial resistance pressures, diagnostic innovation, regulatory evolution, and supply chain recalibration has created a complex but navigable landscape for beta-lactam and beta-lactamase inhibitor development and deployment. Therapeutic success will depend not only on scientific novelty but also on the ability to demonstrate actionable clinical value, maintain reliable supply, and integrate seamlessly with stewardship and diagnostic workflows. Organizations that align R&D priorities with diagnostic capabilities, that invest in supply chain resilience, and that engage proactively with payers and health systems will be positioned to deliver both clinical benefit and sustainable commercial performance.

Looking ahead, the sector is likely to favor pragmatic innovation that restores or extends the utility of established beta-lactams while minimizing collateral selection pressure and preserving access. Collaborative models that distribute risk and leverage complementary competencies will remain central to advancing novel inhibitors into practice. Ultimately, stakeholders who translate deep clinical insight into operational readiness and evidence-aligned value propositions can simultaneously advance patient outcomes and create durable strategic advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Beta Lactam & Beta Lactamase Inhibitors Market, by Drug Class

  • 8.1. Carbapenems
    • 8.1.1. Doripenem
    • 8.1.2. Ertapenem
    • 8.1.3. Imipenem
    • 8.1.4. Meropenem
  • 8.2. Cephalosporins
    • 8.2.1. Fifth-Generation Cephalosporins
    • 8.2.2. First-Generation Cephalosporins
    • 8.2.3. Fourth-Generation Cephalosporins
    • 8.2.4. Second-Generation Cephalosporins
    • 8.2.5. Third-Generation Cephalosporins
  • 8.3. Monobactam
  • 8.4. Penicillins
    • 8.4.1. Aminopenicillins
    • 8.4.2. Extended-Spectrum Penicillins
    • 8.4.3. Natural Penicillins

9. Beta Lactam & Beta Lactamase Inhibitors Market, by Route of Administration

  • 9.1. Oral Administration
    • 9.1.1. Capsules
    • 9.1.2. Tablets
  • 9.2. Parenteral Administration
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous

10. Beta Lactam & Beta Lactamase Inhibitors Market, by Patient Type

  • 10.1. Adult Patients
    • 10.1.1. Middle-Aged Adults
    • 10.1.2. Senior Adults
    • 10.1.3. Young Adults
  • 10.2. Pediatric Patients
    • 10.2.1. Adolescents
    • 10.2.2. Children
    • 10.2.3. Infants
    • 10.2.4. Neonates

11. Beta Lactam & Beta Lactamase Inhibitors Market, by Application

  • 11.1. Gynecological Infections
  • 11.2. Intrabdominal Infections
  • 11.3. Intraoperative Prophylaxis
  • 11.4. Respiratory Infections
  • 11.5. Skin Infections
    • 11.5.1. Cellulitis
    • 11.5.2. Erysipelas
    • 11.5.3. Impetigo
  • 11.6. Urinary Tract Infections
    • 11.6.1. Acute UTI
    • 11.6.2. Chronic UTI

12. Beta Lactam & Beta Lactamase Inhibitors Market, by End User

  • 12.1. Academic Institutions
  • 12.2. Clinics
  • 12.3. Hospitals
  • 12.4. Research Laboratories

13. Beta Lactam & Beta Lactamase Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Beta Lactam & Beta Lactamase Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Beta Lactam & Beta Lactamase Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Beta Lactam & Beta Lactamase Inhibitors Market

17. China Beta Lactam & Beta Lactamase Inhibitors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Aurobindo Pharma Limited
  • 18.7. Bio-Rad Laboratories, Inc.
  • 18.8. Bristol-Myers Squibb Company
  • 18.9. Centrient Pharmaceuticals Netherlands B.V.
  • 18.10. Cipla Ltd.
  • 18.11. Creative Diagnostics
  • 18.12. F. Hoffmann-La Roche AG
  • 18.13. Marubeni Corporation
  • 18.14. Melinta Therapeutics, LLC
  • 18.15. Merck KGaA
  • 18.16. Novartis AG
  • 18.17. Pfizer Inc.
  • 18.18. Protech Telelinks
  • 18.19. Qpex Biopharma, Inc. by Shionogi Inc.
  • 18.20. SciClone Pharmaceuticals (Holdings) Limited
  • 18.21. Sumitomo Pharma Co., Ltd.
  • 18.22. Thermo Fisher Scientific Inc.
  • 18.23. TOKU-E
  • 18.24. Venatorx Pharmaceuticals, Inc.
  • 18.25. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DORIPENEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DORIPENEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DORIPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERTAPENEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERTAPENEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERTAPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMIPENEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMIPENEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMIPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MEROPENEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MEROPENEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MEROPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIFTH-GENERATION CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIFTH-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIFTH-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIRST-GENERATION CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIRST-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIRST-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FOURTH-GENERATION CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FOURTH-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FOURTH-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SECOND-GENERATION CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SECOND-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SECOND-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY THIRD-GENERATION CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY THIRD-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY THIRD-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY AMINOPENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY AMINOPENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY AMINOPENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY EXTENDED-SPECTRUM PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY EXTENDED-SPECTRUM PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY EXTENDED-SPECTRUM PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NATURAL PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NATURAL PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NATURAL PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SENIOR ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SENIOR ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SENIOR ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY YOUNG ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY YOUNG ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INFANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INFANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NEONATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NEONATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NEONATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GYNECOLOGICAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GYNECOLOGICAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GYNECOLOGICAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRABDOMINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRABDOMINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRABDOMINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAOPERATIVE PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAOPERATIVE PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAOPERATIVE PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CELLULITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CELLULITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CELLULITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERYSIPELAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERYSIPELAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERYSIPELAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMPETIGO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMPETIGO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMPETIGO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ACUTE UTI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ACUTE UTI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ACUTE UTI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHRONIC UTI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHRONIC UTI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHRONIC UTI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MIL